AIS BIOTECH
Startup
AIS Biotech (AIS stands for Anti Infective Sugar) is a French biotech company created in March 2023, intending to develop a new class of sugar-based anti-infective biotherapeutics. Our mission is to combat current and emerging infectious diseases.
AIS Biotech aims to develop a pipeline of innovative sugar-based biopharmaceuticals which can prevent or treat microbial infections by mimicking the natural host surface oligosaccharides, the infection front door of several pathogens. Our technology leverages the cell factory approach developed by a leading-edge academic laboratory which use metabolically engineered bacteria to produce defined complex glycans.
GlycoFlu, our first preclinically validated drug candidate aims at preventing or treating human Influenza virus infections. The Flu is still a global public health concern with a significant socio-economic impact while there is a lack of treatment available on the market.
Beyond GlycoFlu, AIS Biotech aims to develop a pipeline of new anti-infective sugar-based biotherapies.
Many pathogenic microorganisms use oligosaccharides as receptors to bind and enter the host cells. The strategy developed for Influenza viruses could be adapted to other viruses or bacteria, such as certain coronaviruses or bacteria that recognize complex sugars as host-cell receptors for infection.
AIS Biotech aims to develop a pipeline of innovative sugar-based biopharmaceuticals which can prevent or treat microbial infections by mimicking the natural host surface oligosaccharides, the infection front door of several pathogens. Our technology leverages the cell factory approach developed by a leading-edge academic laboratory which use metabolically engineered bacteria to produce defined complex glycans.
GlycoFlu, our first preclinically validated drug candidate aims at preventing or treating human Influenza virus infections. The Flu is still a global public health concern with a significant socio-economic impact while there is a lack of treatment available on the market.
Beyond GlycoFlu, AIS Biotech aims to develop a pipeline of new anti-infective sugar-based biotherapies.
Many pathogenic microorganisms use oligosaccharides as receptors to bind and enter the host cells. The strategy developed for Influenza viruses could be adapted to other viruses or bacteria, such as certain coronaviruses or bacteria that recognize complex sugars as host-cell receptors for infection.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events